Allergic Rhinitis
Conditions
Interventions
CSGB group:ultrasound guided cervical sympathetic ganglion block with single injection of 6ml 0.5% ropivacaine
control group:medication alone
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Age =18 years and <65 years. 2. According to the Allergic Rhinitis and its Impact on Asthma (ARIA) classification of rhinitis(2016 revision), patients who were clinical diagnosed as moderate-to-severe Allergic Rhinitis (causing interference with usual daily activities or sleep) and requiring intranasal corticosteroids, oral or intranasal H1-antihistamines and/or oral leukotriene antagonists for more than 4 weeks; 3. Two or more of the following symptoms of allergic rhinitis (sneezing, rhinorrhoea, nasal itching and nasal obstruction) and Total nasal symptom score [TNSS]=4 on a 12-point scale;
Exclusion criteria
Exclusion criteria: 1. History of cervical sympathetic ganglion block and other nerve blockade procedures in the prior 30 days 2. Patients with contraindications of cervical sympathetic ganglion block, including severe cardiovascular and cerebrovascular diseases at acute stage, elderly patients with frailty, history of chronic bronchitis or bronchial asthma complicated with severe emphysema or persistent cough, history of epilepsy or incooperative patients, history of coagulation disorders or obvious hemorrhage tendency, history of glaucoma, and patients with local uncontrolled infection; 3. Allergic to local anesthetic; 4. Other nasal diseases leading to rhinitis include non-allergic rhinitis, chronic sinusitis with / without polyps, and severe deviation of nasal septum requiring surgical intervention; 5. Previous treatment by allergen-specific immunotherapy within the prior 5 years; 6. Previous treatment by systemic corticosteroids (oral or IV) within the prior 3 months; 7. A history of nasal or ocular surgery in the prior 30 days; 8. Women who are pregnant or breastfeeding, or willing to have children in the next 6 months 9. ASA classification >= IV; 10. Other situations that the investigators evaluate unsuitability of participating in this study, such as expected survival less than 3 months; 11. Severe dementia, language disorder or end-stage disease due to inability of cooperation or communication; 12.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The score of CSM-nose at 4 weeks after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| The score of CSM-nose at 2 days after treatment;The scores of CSMS-eye at 2 days and 7 days after treatment;The symptoms scores of VAS at 2 days and 7 days after treatment;The symptoms scores of TNSS at 2 days and 7 days after treatment;The symptoms scores of TESS at 2 days and 7 days after treatment;The medication scores at 2 days and 7 days after treatment;The modified Lund-Kennedy score at 7 days after treatment;Exhaled nitric oxide and nasal resistanceat 7 days after treatment;The score of rhinoconjunctivitis quality of life questionnaire at 7 days after treatment;The score of patient global impression of change at 7 days after treatment;White blood cell, neutrophil, eosinophil, lymphocyte counts and percentages in the blood and nasal secretion at 7 days after treatment;The concentration of IgE and IgG4 in serum and nasal secretion at 7 days after treatment;The concentration of IL-4, IL-5, IL-13, Eosinophilic cationic protein and periostin in Serum at 7 days after treatment;Lymphocyte subset in the peripheral blood at 7 days after treatment; | — |
Countries
China
Contacts
Public ContactZeng-Mao Lin
Peking University First Hospital
Outcome results
None listed